← Back to Screener
Cyclerion Therapeutics, Inc. Common Stock (CYCN)
Price$3.00
Favorite Metrics
Price vs S&P 500 (26W)20.87%
Price vs S&P 500 (4W)80.44%
Market Capitalization$13.08M
All Metrics
Book Value / Share (Quarterly)$2.38
P/TBV (Annual)0.48x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)8.36%
Cash Flow / Share (Quarterly)$-0.87
Price vs S&P 500 (YTD)133.66%
Net Profit Margin (TTM)-170.11%
EPS (TTM)$-1.18
10-Day Avg Trading Volume0.91M
EPS Excl Extra (TTM)$-1.18
Revenue Growth (5Y)-2.05%
EPS (Annual)$-1.11
ROI (Annual)-38.83%
Net Profit Margin (5Y Avg)-1544.15%
Cash / Share (Quarterly)$0.85
Revenue Growth QoQ (YoY)-43.24%
ROA (Last FY)-35.33%
Revenue Growth TTM (YoY)3.70%
EBITD / Share (TTM)$-1.15
ROE (5Y Avg)-129.39%
Operating Margin (TTM)-176.28%
Cash Flow / Share (Annual)$-0.87
P/B Ratio1.44x
P/B Ratio (Quarterly)0.55x
Net Income / Employee (Annual)$-4
EV / Revenue (TTM)4.74x
Net Interest Coverage (TTM)-2581.50x
ROA (TTM)-35.62%
EPS Incl Extra (Annual)$-1.11
Current Ratio (Annual)5.15x
Quick Ratio (Quarterly)4.72x
3-Month Avg Trading Volume4.20M
52-Week Price Return12.69%
Revenue / Employee (TTM)$2
Tangible BV / Share (Quarterly)$5.26
P/S Ratio (Annual)6.31x
Asset Turnover (Annual)0.21x
52-Week High$8.48
Operating Margin (5Y Avg)-1581.10%
EPS Excl Extra (Annual)$-1.11
26-Week Price Return29.61%
Quick Ratio (Annual)4.72x
13-Week Price Return98.68%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.15x
Enterprise Value$9.838
Revenue / Share Growth (5Y)-15.50%
Asset Turnover (TTM)0.21x
Book Value / Share Growth (5Y)-41.60%
Revenue / Employee (Annual)$2
Pretax Margin (Annual)-170.11%
Cash / Share (Annual)$0.85
3-Month Return Std Dev624.46%
Net Income / Employee (TTM)$-4
ROE (Last FY)-38.83%
EPS Basic Excl Extra (Annual)$-1.11
Receivables Turnover (TTM)2.67x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.18
Receivables Turnover (Annual)2.67x
ROI (TTM)-39.23%
P/S Ratio (TTM)6.31x
Pretax Margin (5Y Avg)-1544.15%
Revenue / Share (Annual)$0.65
Tangible BV / Share (Annual)$4.80
Price vs S&P 500 (52W)-22.41%
Year-to-Date Return137.80%
5-Day Price Return4.50%
EPS Normalized (Annual)$-1.11
ROA (5Y Avg)-87.45%
Net Profit Margin (Annual)-170.11%
Month-to-Date Return94.84%
Cash Flow / Share (TTM)$-7.92
EBITD / Share (Annual)$-1.15
Operating Margin (Annual)-176.28%
ROI (5Y Avg)-129.39%
EPS Basic Excl Extra (TTM)$-1.18
P/TBV (Quarterly)0.39x
P/B Ratio (Annual)0.55x
Pretax Margin (TTM)-170.11%
Book Value / Share (Annual)$2.38
Price vs S&P 500 (13W)95.82%
Beta1.60x
Revenue / Share (TTM)$0.54
ROE (TTM)-39.23%
52-Week Low$1.03
Analyst Recommendations
Feb 2023
Mar 2023
Apr 2023
May 2023
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CYCNCyclerion Therapeutics, Inc. Common Stock | 6.31x | 3.70% | — | — | $3.00 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases using soluble guanylate cyclase (sGC) stimulator technology. The company's pipeline includes Olinciguat, Praliciguat, and other candidates targeting rare disease indications. Cyclerion is focused on advancing next-generation sGC stimulators to address unmet medical needs in patients with limited treatment options.